ArticlePloS one2013
Cholera toxin enhances vaccine-induced protection against Mycobacterium tuberculosis challenge in mice.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Review
- Broad protective vaccination against systemic Escherichia coli with autotransporter antigens.PLoS pathogens · 2023Article
- Interleukin-23 instructs protective multifunctional CD4 T cell responses after immunization with the Mycobacterium tuberculosis subunit vaccine H1 DDA/TDB independently of interleukin-17A.Journal of molecular medicine (Berlin, Germany) · 2021Article
- Targeting Unconventional Host Components for Vaccination-Induced Protection Against TB.Frontiers in immunology · 2020Review
- Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges.Expert review of vaccines · 2019Review
- Mucosal boosting of H56:CAF01 immunization promotes lung-localized T cells and an accelerated pulmonary response to Mycobacterium tuberculosis infection without enhancing vaccine protection.Mucosal immunology · 2019Article
- Article
- Rationalized design of a mucosal vaccine protects againstJournal of leukocyte biology · 2017Article
- U-Omp19 fromFrontiers in immunology · 2017Article
- Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice.Journal of visualized experiments : JoVE · 2016Article
- Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates.Advanced drug delivery reviews · 2016Review
- Immune requirements for protective Th17 recall responses to Mycobacterium tuberculosis challenge.Mucosal immunology · 2015Article
- Novel vaccine approaches for protection against intracellular pathogens.Current opinion in immunology · 2014Review
- Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites.Human vaccines & immunotherapeutics · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Interleukin (IL)-17 is emerging as an important cytokine in vaccine-induced protection against tuberculosis disease in animal models. Here we show that compared to parenteral delivery, BCG delivered mucosally enhances cytokine production, including interferon gamma and IL-17, in the lungs. Furthermore, we find that cholera toxin, delivered mucosally along with BCG, further enhances IL-17 production by CD4(+) T cells over mucosal BCG alone both in the lungs and systemically. This boosting effect of CT is also observed using a vaccine regimen of BCG followed by the candidate vaccine MVA85A. Using a murine Mycobacterium tuberculosis (M.tb) aerosol challenge model, we demonstrate the ability of cholera toxin delivered at the time of a priming BCG vaccination to improve protection against tuberculosis disease in a manner at least partially dependent on the observed increase in IL-17. This observed increase in IL-17 in the lungs has no adverse effect on lung pathology following M.tb challenge, indicating that IL-17 can safely be boosted in murine lungs in a vaccine/M.tb challenge setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.